Skip to main content

Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist.

Publication ,  Journal Article
Davis, WB; Wells, SR; Kuller, JA; Thorp, JM
Published in: Obstet Gynecol Surv
March 1997

Calcium channel antagonists are widely prescribed in obstetrics and gynecology for blood pressure control and tocolysis. Concerns have recently arisen regarding the safety of these agents. Several studies found that short-acting forms of calcium channel blockers were associated with increased cardiovascular mortality, malignancy, and gastrointestinal bleeding. A recent meta-analysis found a significant increase in the risk of mortality in patients treated with a short-acting form of nifedipine. Another subgroup analysis of an observational study of older hypertensive patients found a significantly increased risk of cancer and gastrointestinal hemorrhage in patients prescribed calcium channel blockers. Both in vitro and small human in vitro series have reported a potential for cardiac toxicity in pregnant women treated concomitantly with calcium channel blockers and magnesium sulfate. Until additional data are available, we suggest that when calcium channel blockers are used in obstetrics and gynecology, the long-acting variety be prescribed. Concurrent use of calcium channel blockers and magnesium sulfate should be undertaken cautiously because of the potential for synergistic depression of cardiac function.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Obstet Gynecol Surv

DOI

ISSN

0029-7828

Publication Date

March 1997

Volume

52

Issue

3

Start / End Page

198 / 201

Location

United States

Related Subject Headings

  • Tocolytic Agents
  • Pregnancy Complications
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Nifedipine
  • Neoplasms
  • Magnesium Sulfate
  • Humans
  • Heart Diseases
  • Gastrointestinal Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davis, W. B., Wells, S. R., Kuller, J. A., & Thorp, J. M. (1997). Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet Gynecol Surv, 52(3), 198–201. https://doi.org/10.1097/00006254-199703000-00023
Davis, W. B., S. R. Wells, J. A. Kuller, and J. M. Thorp. “Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist.Obstet Gynecol Surv 52, no. 3 (March 1997): 198–201. https://doi.org/10.1097/00006254-199703000-00023.
Davis WB, Wells SR, Kuller JA, Thorp JM. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet Gynecol Surv. 1997 Mar;52(3):198–201.
Davis, W. B., et al. “Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist.Obstet Gynecol Surv, vol. 52, no. 3, Mar. 1997, pp. 198–201. Pubmed, doi:10.1097/00006254-199703000-00023.
Davis WB, Wells SR, Kuller JA, Thorp JM. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet Gynecol Surv. 1997 Mar;52(3):198–201.

Published In

Obstet Gynecol Surv

DOI

ISSN

0029-7828

Publication Date

March 1997

Volume

52

Issue

3

Start / End Page

198 / 201

Location

United States

Related Subject Headings

  • Tocolytic Agents
  • Pregnancy Complications
  • Pregnancy
  • Obstetrics & Reproductive Medicine
  • Nifedipine
  • Neoplasms
  • Magnesium Sulfate
  • Humans
  • Heart Diseases
  • Gastrointestinal Hemorrhage